Nikolas Plevris
@PlevrisN
Followers
494
Following
1K
Media
15
Statuses
258
Consultant Gastroenterologist The Edinburgh IBD Unit Western General Hospital Edinburgh, UK
Edinburgh, Scotland
Joined November 2012
In Lothian, UK (2004–2023), colectomy rates in UC fell sharply as advanced therapy use rose—colectomies dropped from 2.48 to 0.22 per 100 UC pts; first-line biologics up from 0 to 2.82%. Read the full paper in @APandT (open access) via https://t.co/oGLqK0FvZK
#IBD #UC #GITwitter
1
8
26
Exciting Opportunity: Data Scientist - IBD Research Team We're expanding our world-class research team @EdinUni_IGC What we're building: An AI-driven dynamic clinical decision support tool that will transform how we predict and manage outcomes for IBD patients globally. Who
elxw.fa.em3.oraclecloud.com
We are seeking a Postdoctoral Research Associate in Health Data Science to join our team in the Institute of Genetics and Cancer. In this role, you will develop and apply cutting-edge data science...
1
10
22
Our letter published in @Gut_BMJ comparing the 4 RCTs of anti-TNF withdrawal in #IBD in light of the EXIT trial. @ShahidaDin1
@TakuKobayashiM1
@AaronBancil
@PlevrisN
https://t.co/IF07qy96nX
1
12
28
Here are the links to the two full papers https://t.co/UR10i3G6oU
https://t.co/afEQJ2dglp
@PlevrisN @DrNickKennedy @UoE_CGEM
cghjournal.org
The level of fecal calprotectin (FC) correlates with endoscopic evidence of inflammation in Crohn’s disease (CD). A treat-to-target algorithm for patients with CD, that incorporates FC, outperforms a...
0
4
8
📢 Thrilled to share our latest study in @JCC_IBD Tofacitinib vs vedolizumab as first-line advanced therapies in #UC ➡️ https://t.co/qn4IvPXjXX
#IBD Grateful to work with this team ❤️@charlie_lees @PlevrisN @IBDNathan @claire_ohare_ @Gastro_GRJ @_Jake_15
7
38
110
Check out latest study by Elford et al. on the real-world effectiveness of Upadacitinib in Crohn's disease. Their findings underscore Upa as a promising rx option for medically refractory CD link: https://t.co/oa7K9LalVH
@AlexElford3, @PlevrisN, @DrNickKennedy @MohsenSubhani
0
4
5
Upadacitinib for Crohn's disease • data from Edinburgh and Exeter • n=93 with median 25w follow-up • effective in highly refractory cohort See 👇 for figures and link @FrontGastro_BMJ
4
37
125
I’ve been working with the British Society for Immunology (BSI) to develop a new online training course on IBD immunology in clinical practice. The first gastroenterology day is on 5th June; details 👉 https://t.co/767Kb8bPmG
@bsicongress @jimbrewer84 @PlevrisN @Bealoquebea
8
29
83
Cross disciplinary team effort 💪🏽Drs Iona Campbell& Michael Glinka, @ShabanFadlo, DrsKate Kirkwood & Francesca Nadalin @David_J_Adams @PathologyEdin @irenepapatheodo Profs Baldock & Burger. 🙌🏽All the amazing & incredibly talented people who make this possible.
Excellent review article on fibrosis in Crohns by @shahidadin1 . JCM | Free Full-Text | The Promise of Single-Cell RNA Sequencing to Redefine the Understanding of Crohn’s Disease Fibrosis Mechanisms
1
5
16
One of the best courses I have been on! Fantastic weekend, in beautiful Luneburg, learning new skills to help improve the care of our patients living with IBD. @BowelUltrasound #IUS
2
0
20
The author-corrected version of our @AGA_CGH paper is now available (open access)! https://t.co/cgLAqaf8Ow
1
4
10
Happy to announce our #IBD research, in which we use faecal calprotectin over time to characterise Crohn's disease heterogeneity, is now available as an article in press with @AGA_CGH! (Open access and proofed versions to follow at a later date) https://t.co/iHSd2aO6sC
3
10
55
Not at #ECCO23 this year? This is our poster in which we identify distinctive faecal calprotectin profiles in IBD with over 2400 subjects (WIP, subject to change). We are looking for collaborators for validation/external cohorts! Interested? Please contact me or @charlie_lees.
7
11
51
Multiple successive switches from IFX originator to biosimilars are effective and safe in patients with IBD, irrespective of the number of IFX switches. 🧵 Our paper is open for you to read. https://t.co/ZzGLbHZgiK
7
39
148
Phenomenal resource created by the superstar that is @Bealoquebea. Always striving to improve the care of IBD patients worldwide!
Many of you know I love timelines & I have been updating the one on IBD trials/studies for some time🧵 The landscape is changing fast & there isnt enough space here to share all the content As such I have created a website to collect it all and to make it interactive
1
0
8
This 🙌
0
0
4
In times of ⏫healthcare💰, check this out: N=297 IBD 🏴 Multiple IFX originator to biosimilars switches demonstrated comparable: 1⃣ Clinical remission 2⃣ Biochemical (CRP) remission 3⃣ Faecal calprotectine values ➡️This will help reduce💰! @UEGJournal 🔜 to be published🔥
2
16
43
We reported our experience with UST in the Edinburgh IBD unit 1/3 of CD patients underwent UST dose intensification to 4- or 6-weekly <1y Risk factors for dose intensification: - Anti-TNF and Vedo failure - corticosteroid use at UST initiation @charlie_lees 🧵👇
4
16
73